Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Neuro-2
- Development stage
- Preclinical
- Lead developer
- Interdict Bio
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Neuro-2 is an early-stage small molecule therapeutic being developed by Interdict Bio for the treatment of Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). It belongs to a novel class of drugs termed 'Interdictors,' which are designed to be orally bioavailable and selectively inhibit protein synthesis. The mechanism of action involves a context-dependent interaction with nascent polypeptides within the ribosome, allowing for the modulation of specific proteins involved in ALS/FTD pathways that are typically considered undruggable. The program is currently in the hit-to-lead phase of development and is part of Interdict Bio's broader strategy to target neurodegenerative diseases using its proprietary ribosome-targeting platform.
- Other names
- Interdict Bio ALS/FTD program
02
Targets
28S rRNA (28S ribosomal RNA)
Beyond the preview
Go deeper on Neuro-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neuro-2.